Monday, June 3, 2024, 7:00 AM – 8:00 AM Central Time (8:00 AM – 9:00 AM Eastern Time)

RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal Cancer

A CME-Accredited Virtual Event Held in Conjunction with the 2024 ASCO Annual Meeting

Join us on Monday, June 3rd for this CME-accredited webinar
7:00 AM – 8:00 AM CT

Scott Kopetz, MD, PhD
Deputy Chair for Translational Research
Department of Gastrointestinal Medical Oncology
Associate Vice President
for Translational Integration
The University of Texas
MD Anderson Cancer Center
Houston, Texas

John Strickler, MD
Associate Professor
Associate Director, Clinical Research – GI
Duke University
Durham, North Carolina

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from Bristol Myers Squibb and Natera Inc.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Monday, June 3, 2024
7:00 AM – 8:00 AM CT
Live CME-accredited webinar

Discussion Topics

  • New Developments in Targeted Therapy for Metastatic Colorectal Cancer (CRC)
  • Other Recent Therapeutic Advances in CRC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of colorectal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering the influence of various clinical and biological factors, such as age, performance status and stage, and the potential relevance of molecular residual disease.
  • Develop an understanding of validated biomarkers of response found in patients with metastatic CRC (mCRC), such as RAS, BRAF, HER2 and microsatellite instability/mismatch repair deficiency, and consider the implications for molecular testing and clinical care.
  • Evaluate available data with immune checkpoint inhibitor therapies for microsatellite instability-high/mismatch repair-deficient mCRC, and optimally select patients for treatment with these approaches.
  • Recognize available data with HER2-targeted therapies for patients with HER2-positive mCRC, and consider the current and future role of these approaches.
  • Develop an understanding of available trial findings with novel small-molecule inhibitors of KRAS G12C in combination with anti-EGFR monoclonal antibody therapy for patients with previously treated mCRC harboring a KRAS G12C mutation to determine the applicability of this strategy in clinical practice.
  • Apply available research to optimize the selection and sequencing of later-line therapeutic options for patients with relapsed/refractory mCRC, considering the implications of recently approved agents and regimens.
  • Recall ongoing trials evaluating novel agents and strategies for patients with mCRC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit form link will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr KopetzConsulting Agreements: Agenus Inc, Amgen Inc, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Carina Biotech, Flame Biosciences, Frontier Medicines, Genentech, a member of the Roche Group, Harbinger Health, Kestrel Therapeutics, Lutris Pharma, Merck, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Replimune, Revolution Medicines, Roche Laboratories Inc, Tachyon Therapeutics, Tempus, Zentalis Pharmaceuticals; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BridgeBio, Cardiff Oncology, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Guardant Health, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Sanofi, Zentalis Pharmaceuticals. Dr StricklerAdvisory Committees: AbbVie Inc, Agenus Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, A*STAR D3, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, BeiGene Ltd, GSK, Pfizer Inc; Stock Options — Private Company: Triumvira Immunologics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Bristol Myers Squibb and Natera Inc.